GT Biopharma Begins Manufacturing of "Non-Opioid" Pain-Brake Drug to Compete in Multi-Billion Dollar Chronic Pain Market October 17, 2017
GT Biopharma Announces Completion of First Four Patients in FDA Phase 2 Trial of Cancer Drug OXS-1550 October 10, 2017
GT Biopharma, Inc. Announces Corporate Update Conference Call with CEO Dr. Kathleen Clarence-Smith, CMO Dr. Raymond Urbanski and Chairman Anthony Cataldo September 27, 2017
GT Biopharma Announces Development Plan For Non-Opioid Neuropathic Pain Treatment "PainBrake" September 11, 2017
GT Biopharma Hires Former Pfizer CMO/Vice President and Senior Director of Oncology Research as Chief Medical Officer September 7, 2017
GT Biopharma, Inc, Announces Closing of OXIS International - Georgetown Translational Pharmaceuticals Merger September 5, 2017
GT Biopharma, Inc. Announces Reverse Stock Spilt As Part of Oxis-Georgetown Planned Merger August 21, 2017